RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
ARCA Biopharma Stock

ARCA Biopharma Stocks 2024

ARCA Biopharma Stocks

14.42 M

Ticker

ABIO

ISIN

US00211Y5069

WKN

A2PGY6

In 2024, ARCA Biopharma had 14.42 M outstanding stocks, a 0% change from the 14.42 M stocks in the previous year.

The ARCA Biopharma Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2026e14.42
2025e14.42
2024e14.42
202314.42
202214.41
202113.9
20204.71
20191.32
20180.77
20170.58
20160.5
20150.35
20140.16
20130.07
20120.02
20110.01
20100.01
20090.01
2008-
2007-
2006-
2005-
2004-

ARCA Biopharma shares outstanding

The number of shares was ARCA Biopharma in 2023 — This indicates how many shares 14.416 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue ARCA Biopharma earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates ARCA Biopharma's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of ARCA Biopharma’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating ARCA Biopharma's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

ARCA Biopharma Aktienanalyse

What does ARCA Biopharma do?

ARCA Biopharma Inc. is a biopharmaceutical company specializing in the development of therapies for cardiovascular diseases. The company was founded in 2004 and is headquartered in Westminster, Colorado, USA. ARCA Biopharma develops novel drugs tailored to the needs of patients with cardiovascular diseases. The history of ARCA Biopharma began when the company acquired exclusive rights to a technology for identifying genetic mutations associated with increased susceptibility to cardiovascular diseases. Thanks to this technology, ARCA Biopharma was able to develop more targeted, effective therapies based on the patient's genetic makeup. ARCA Biopharma's business model is based on the development of therapeutic technologies for cardiovascular diseases. The company utilizes its expertise in genomic research to develop customized, innovative drug therapies that are more targeted to the patient's genetic needs. ARCA Biopharma conducts intensive research and development work to develop significantly more effective drugs that are aimed at revolutionizing the market. ARCA Biopharma offers various types of medical therapies tailored to the needs of patients with cardiovascular diseases. The company focuses on RNA drug development and genomic research. RNA drugs are a relatively new type of medical therapy based on the regulation of gene expression. The company has several products in various stages of development tailored to the needs of patients with cardiovascular diseases. One of ARCA Biopharma's most successful products is Gencaro, a novel drug used in the treatment of heart failure. Gencaro is a beta-blocker specifically designed for patients with genetic markers associated with increased susceptibility to cardiovascular diseases. ARCA Biopharma has received multiple awards and numerous accolades for its innovation and research work. The company has partnerships with leading research and development organizations around the world to maximize its research efforts and accelerate the development of new innovative drugs. Overall, ARCA Biopharma aims to improve the lives of patients with cardiovascular diseases by providing tailored therapies that meet the genetic needs of the patient. The company has gained a reputation for its innovative research work and the development of highly effective drugs, and will undoubtedly play a leading role in the future development of therapies for cardiovascular diseases. ARCA Biopharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating ARCA Biopharma's Shares Outstanding

ARCA Biopharma's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in ARCA Biopharma’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding ARCA Biopharma’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in ARCA Biopharma’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about ARCA Biopharma stock

How many stocks are there of ARCA Biopharma?

The current number of stocks of ARCA Biopharma is 14.42 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of ARCA Biopharma are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of ARCA Biopharma evolved in recent years?

The number of shares of ARCA Biopharma has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. ARCA Biopharma as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of ARCA Biopharma?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does ARCA Biopharma pay?

Over the past 12 months, ARCA Biopharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ARCA Biopharma is expected to pay a dividend of 0 USD.

What is the dividend yield of ARCA Biopharma?

The current dividend yield of ARCA Biopharma is .

When does ARCA Biopharma pay dividends?

ARCA Biopharma pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of ARCA Biopharma?

ARCA Biopharma paid dividends every year for the past 0 years.

What is the dividend of ARCA Biopharma?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is ARCA Biopharma located?

ARCA Biopharma is assigned to the 'Health' sector.

Wann musste ich die Aktien von ARCA Biopharma kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of ARCA Biopharma from 8/28/2024 amounting to 1.613 USD, you needed to have the stock in your portfolio before the ex-date on 8/29/2024.

When did ARCA Biopharma pay the last dividend?

The last dividend was paid out on 8/28/2024.

What was the dividend of ARCA Biopharma in the year 2023?

In the year 2023, ARCA Biopharma distributed 0 USD as dividends.

In which currency does ARCA Biopharma pay out the dividend?

The dividends of ARCA Biopharma are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The ARCA Biopharma stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von ARCA Biopharma

Our stock analysis for ARCA Biopharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ARCA Biopharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.